These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 25680760)

  • 1. Vorapaxar in atherosclerotic disease management.
    Cheng JW; Colucci V; Howard PA; Nappi JM; Spinler SA
    Ann Pharmacother; 2015 May; 49(5):599-606. PubMed ID: 25680760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of vorapaxar as approved for clinical use in the United States.
    Magnani G; Bonaca MP; Braunwald E; Dalby AJ; Fox KA; Murphy SA; Nicolau JC; Oude Ophuis T; Scirica BM; Spinar J; Theroux P; Morrow DA
    J Am Heart Assoc; 2015 Mar; 4(3):e001505. PubMed ID: 25792124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vorapaxar for reduction of thrombotic cardiovascular events in myocardial infarction and peripheral artery disease.
    Arif SA; D'Souza J; Gil M; Gim S
    Am J Health Syst Pharm; 2015 Oct; 72(19):1615-22. PubMed ID: 26386102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of selective platelet inhibition in reducing cardiovascular risk - role of vorapaxar.
    Cheng JW
    Vasc Health Risk Manag; 2016; 12():263-8. PubMed ID: 27366081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vorapaxar: A Protease-Activated Receptor Antagonist for the Prevention of Thrombotic Events.
    Lam S; Tran T
    Cardiol Rev; 2015; 23(5):261-7. PubMed ID: 25923910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vorapaxar in the secondary prevention of atherothrombotic events.
    Morrow DA; Braunwald E; Bonaca MP; Ameriso SF; Dalby AJ; Fish MP; Fox KA; Lipka LJ; Liu X; Nicolau JC; Ophuis AJ; Paolasso E; Scirica BM; Spinar J; Theroux P; Wiviott SD; Strony J; Murphy SA;
    N Engl J Med; 2012 Apr; 366(15):1404-13. PubMed ID: 22443427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vorapaxar in the secondary prevention of atherothrombosis.
    Tantry US; Liu F; Chen G; Gurbel PA
    Expert Rev Cardiovasc Ther; 2015 Dec; 13(12):1293-305. PubMed ID: 26559689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vorapaxar: a review of its use in the long-term secondary prevention of atherothrombotic events.
    Frampton JE
    Drugs; 2015 May; 75(7):797-808. PubMed ID: 25895464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atherothrombotic Risk Stratification and the Efficacy and Safety of Vorapaxar in Patients With Stable Ischemic Heart Disease and Previous Myocardial Infarction.
    Bohula EA; Bonaca MP; Braunwald E; Aylward PE; Corbalan R; De Ferrari GM; He P; Lewis BS; Merlini PA; Murphy SA; Sabatine MS; Scirica BM; Morrow DA
    Circulation; 2016 Jul; 134(4):304-13. PubMed ID: 27440003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes.
    Tricoci P; Huang Z; Held C; Moliterno DJ; Armstrong PW; Van de Werf F; White HD; Aylward PE; Wallentin L; Chen E; Lokhnygina Y; Pei J; Leonardi S; Rorick TL; Kilian AM; Jennings LH; Ambrosio G; Bode C; Cequier A; Cornel JH; Diaz R; Erkan A; Huber K; Hudson MP; Jiang L; Jukema JW; Lewis BS; Lincoff AM; Montalescot G; Nicolau JC; Ogawa H; Pfisterer M; Prieto JC; Ruzyllo W; Sinnaeve PR; Storey RF; Valgimigli M; Whellan DJ; Widimsky P; Strony J; Harrington RA; Mahaffey KW;
    N Engl J Med; 2012 Jan; 366(1):20-33. PubMed ID: 22077816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review of vorapaxar for the prevention of atherothrombotic events.
    Wang A
    Expert Opin Pharmacother; 2015; 16(16):2509-22. PubMed ID: 26480240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vorapaxar in patients with peripheral artery disease: results from TRA2{degrees}P-TIMI 50.
    Bonaca MP; Scirica BM; Creager MA; Olin J; Bounameaux H; Dellborg M; Lamp JM; Murphy SA; Braunwald E; Morrow DA
    Circulation; 2013 Apr; 127(14):1522-9, 1529e1-6. PubMed ID: 23501976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction in overall occurrences of ischemic events with vorapaxar: results from TRACER.
    White HD; Huang Z; Tricoci P; Van de Werf F; Wallentin L; Lokhnygina Y; Moliterno DJ; Aylward PE; Mahaffey KW; Armstrong PW
    J Am Heart Assoc; 2014 Jul; 3(4):. PubMed ID: 25012288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of age on efficacy and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial.
    Armaganijan LV; Alexander KP; Huang Z; Tricoci P; Held C; Van de Werf F; Armstrong PW; Aylward PE; White HD; Moliterno DJ; Wallentin L; Chen E; Harrington RA; Strony J; Mahaffey KW; Lopes RD
    Am Heart J; 2016 Aug; 178():176-84. PubMed ID: 27502866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of vorapaxar in patients with prior ischemic stroke.
    Morrow DA; Alberts MJ; Mohr JP; Ameriso SF; Bonaca MP; Goto S; Hankey GJ; Murphy SA; Scirica BM; Braunwald E;
    Stroke; 2013 Mar; 44(3):691-8. PubMed ID: 23396280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vorapaxar, a Protease-Activated Receptor-1 Antagonist, a Double-Edged Sword!
    Bhandari B; Mehta B
    Recent Adv Cardiovasc Drug Discov; 2014; 9(2):73-7. PubMed ID: 26104312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vorapaxar: emerging evidence and clinical questions in a new era of PAR-1 inhibition.
    Ungar L; Rodriguez F; Mahaffey KW
    Coron Artery Dis; 2016 Nov; 27(7):604-15. PubMed ID: 27398626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial.
    Scirica BM; Bonaca MP; Braunwald E; De Ferrari GM; Isaza D; Lewis BS; Mehrhof F; Merlini PA; Murphy SA; Sabatine MS; Tendera M; Van de Werf F; Wilcox R; Morrow DA;
    Lancet; 2012 Oct; 380(9850):1317-24. PubMed ID: 22932716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute Limb Ischemia and Outcomes With Vorapaxar in Patients With Peripheral Artery Disease: Results From the Trial to Assess the Effects of Vorapaxar in Preventing Heart Attack and Stroke in Patients With Atherosclerosis-Thrombolysis in Myocardial Infarction 50 (TRA2°P-TIMI 50).
    Bonaca MP; Gutierrez JA; Creager MA; Scirica BM; Olin J; Murphy SA; Braunwald E; Morrow DA
    Circulation; 2016 Mar; 133(10):997-1005. PubMed ID: 26826179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic drug evaluation of vorapaxar for secondary prevention after acute coronary syndrome.
    Perez-Rivera JA; Monedero-Campo J; Cieza-Borrella C; Ruiz-Perez P
    Expert Opin Drug Metab Toxicol; 2017 Mar; 13(3):339-350. PubMed ID: 28135897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.